TY - JOUR ID - 7062 TI - Interferon Resistance of Hepatitis C Virus Genotypes 1a/1b: Relationship to Structural E2 Gene Quasispecies Mutations JO - Iranian Journal of Biotechnology JA - IJB LA - en SN - 1728-3043 AU - Honardoost, Maryam AU - Sabahi, Farzaneh AU - Amini-Bavil-Olyaee, Samad AU - Behzadian, Farida AU - Merat, Shahin AU - Malekzadeh, Reza AD - Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, P.O. Box 14155-111, I.R. Iran AD - Biotechnology Department, Pasteur Institute of Tehran, P.O. Box 13164, I.R. Iran 3Digestive Diseases Research Center, Shariati Hospital, Tehran, P.O. Box 14117-13135, I.R. Iran AD - Digestive Diseases Research Center, Shariati Hospital, Tehran, P.O. Box 14117-13135, I.R. Iran Y1 - 2008 PY - 2008 VL - 6 IS - 1 SP - 36 EP - 44 KW - Hepatitis C Virus KW - E2 glycoprotein KW - PePHD region KW - IFN therapy KW - Treatment resistance DO - N2 - Hepatitis C virus (HCV) envelope glycoprotein-2 (E2) inhibits the interferon (IFN)–induced, double –stranded RNA activated protein kinase (PKR) via PKR eukaryotic initiation factor-2α phosphorylation homology domain (PePHD). Present study examined the genetic variability of the PePHD in patients receiving interferon therapy. The PePHD region from HCV genotype 1a/1b infected patients receiving IFN was amplified by reverse transcriptase polymerase chain reaction (RT-PCR) and analyzed using bidirectionaly sequencing. The PePHD sequence was different in pretreatment isolates from three months treated patients. It was shown that the major PePHD quasispecies could change after three months IFN therapy and in one patient; the major PePHD quasispecies could change after six months IFN therapy. These mutations were occurred at codons 665, 666 and 667 of followed-up samples and at codons 660, 661, 666 and 670 of randomly treated patients. Some of these mutations were similar to those reported in previous studies. Other mutations were also detected in upstream and downstream regions of PePHD which may have influenced the structure, conformation and configuration of this region and thereby suppressing PePHD inhibitory properties. In conclusion our data suggested that HCV E2 PePHD may play an important role in determining the interferon response among Iranian HCV infected patients. UR - https://www.ijbiotech.com/article_7062.html L1 - https://www.ijbiotech.com/article_7062_4cef073e0ce79458e1871bf7e2be3a10.pdf ER -